Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline
Mollie Pleet, Joshua White, Joseph A. Zamaria, Rachel Yehuda
Psychedelic Medicine May 19, 2023 DOI: 10.1089/psymed.2022.0017 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 884 |
| Population | Callers to a psychedelic helpline |
| Intervention | psychedelic helpline |
| Keywords | Helpline Distress Conversation Mental health Medical emergency Internet privacy Clinical psychology Emergency medicine Communication |
| Citations | 12 |
| Key findings | 65.9% of callers reported the helpline de-escalated their psychological distress, and many indicated it prevented potential harm or emergency service use. |
Abstract
Introduction: A resurgence of interest in the use of psychedelics for mental health and wellness has stimulated greater experimentation with psychedelics in society. Although clinical psychedelic trials protect research participants by offering a safe setting, thorough preparation, and containment during and after ingestion of psychedelic medicines, many try these substances without the benefit of these safeguards.
Materials and Methods: We analyzed data gathered from 884 callers to a psychedelic helpline to determine whether a helpline model could reduce the risks associated with nonclinical psychedelics use.
Results: In total, 65.9% of callers indicated that the helpline de-escalated them from psychological distress. If not for their conversation with the helpline, 29.3% of callers indicated they may have been harmed; 12.5% indicated that they may have called 911; and 10.8% indicated they may have gone to the emergency room.
Conclusion: The data suggest that access to a psychedelic helpline surrounding psychedelic experiences may avert harmful outcomes and offset the burden on emergency and medical services.
Citations in the library
Cited by 13
- Psychedelic group-based integration: ethical assessment and initial recommendations International Review of Psychiatry June 5, 2024
- Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022). Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025
- Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda. Psychedelic Medicine December 13, 2023
- Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence. Psychedelic Medicine December 1, 2024
- Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis. Harm Reduction Journal December 9, 2025
and 8 more in the library
Cites 11
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
and 6 more in the library